Sittner & Nelson’s Novavax NVAX Stock Holding History

Sittner & Nelson’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.1K	Hold	223	–	–	﹤0.01%	536
2026 Q1	$1.82K	Hold	223	–	–	﹤0.01%	522
2025 Q4	$1.84K	Hold	223	–	–	﹤0.01%	484
2025 Q3	$1.93K	Hold	223	–	–	﹤0.01%	445
2025 Q2	$1.41K	Hold	223	–	–	﹤0.01%	461
2025 Q1	$1.43K	Hold	223	–	–	﹤0.01%	453
2024 Q4	$1.79K	Sell	223 -450	-67%	-$4.34K	﹤0.01%	426
2024 Q3	$8.5K	Buy	673 +23	+4%	+$297	﹤0.01%	356
2024 Q2	$8.23K	Hold	650	–	–	﹤0.01%	360
2024 Q1	$3.11K	Hold	650	–	–	﹤0.01%	419
2023 Q4	$3.12K	Sell	650 -23	-3%	-$141	﹤0.01%	409
2023 Q3	$4.87K	Hold	673	–	–	﹤0.01%	385
2023 Q2	$5K	Buy	673 +23	+4%	+$181	﹤0.01%	402
2023 Q1	$4.5K	Hold	650	–	–	﹤0.01%	416
2022 Q4	$6.68K	Hold	650	–	–	﹤0.01%	369
2022 Q3	$12K	Hold	650	–	–	0.01%	315
2022 Q2	$33K	Hold	650	–	–	0.02%	248
2022 Q1	$48K	Hold	650	–	–	0.03%	216
2021 Q4	$93K	Hold	650	–	–	0.05%	154
2021 Q3	$135K	Hold	650	–	–	0.09%	118
2021 Q2	$138K	Buy	650 +200	+44%	+$36.6K	0.1%	110
2021 Q1	$82K	Buy	450 +200	+80%	+$39.9K	0.06%	141
2020 Q4	$28K	Buy	+250	New	+$26.6K	0.03%	200

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Sittner & Nelson's NVAX Position: Q2 2026 in Review

Sittner & Nelson held its Novavax (NVAX) position steady in Q2 2026 at 223 shares worth $2.1K. The position accounts for ﹤0.01% of the portfolio, ranked #536.

Sittner & Nelson first reported a position in NVAX in Q4 2020 and has held it in 23 quarters since. The position peaked at $138K in Q2 2021. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Sittner & Nelson held 223 shares of Novavax worth $2.1K as of Q2 2026.
Sittner & Nelson left its Novavax share count unchanged in Q2 2026.
Novavax made up ﹤0.01% of Sittner & Nelson's portfolio in Q2 2026, its #536 holding.
Sittner & Nelson first reported a position in Novavax in Q4 2020 and has held it in 23 quarters since.
Sittner & Nelson's Novavax position peaked at $138K in Q2 2021.
266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Sittner & Nelson's 13F filing for Q2 2026, filed 7 Aug 2026.